For decades, fatty liver disease and its more serious inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), were often overlooked conditions with few approved treatments. Boehringer Ingelheim is among the companies now going after them with a concerted push. “We have a program in MASH, in the liver, the LIVERAGE program, plus a robust data-generation program to…
Immunai’s digital ‘plumbing’ keeps AstraZeneca coming back
Immunai, a startup building a foundation model of the human immune system, has expanded its oncology collaboration with AstraZeneca for the third time. Immunai is eligible to receive up to $37.5 million over 2026 and 2027 under the new agreement, which extends its AMICA-OS platform deeper into AstraZeneca’s clinical development pipeline. The two companies began…
Scientists have discovered a potential new treatment for tuberculosis – even drug-resistant strains
History’s deadliest infectious disease has a new adversary. Although many think of tuberculosis as a disease of the past, it still kills 1.2 million people annually. Last month, scientists at Texas A&M AgriLife Research published a study in Nature, revealing that they had developed a new compound that could be a tuberculosis treatment breakthrough. The…
Deepcell’s CEO forges her own path to transforming cell science with AI and microfluidics
Deepcell co-founder Maddison Masaeli took an unexpected path from academic research to launching an AI-powered cell analysis platform. The company has raised close to $100 million in funding to support its mission. This includes a $73 million Series B round and an earlier $20 million Series A round. The company has entered into a research…
Deepcell’s REM-I platform marries AI with morphological analysis for drug discovery
From her early days as a research assistant at UCLA, to her work as a postdoctoral fellow at Stanford, Deepcell co-founder and CEO Maddison Mahdokht Masaeli has actively engaged in the field of biomedical engineering. Now, Masaeli and her team at Deepcell, a company she co-founded in 2017, are introducing a new strategy to drug…




